Press Releases Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
0.5265 ^USD	-5.27%		+0.80%	-3.09%

Mar. 22	Sangamo Therapeutics Prices $24 Million Registered Direct Offering	MT
Mar. 14	Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast	May. 02	BU
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting	Apr. 23	AQ
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)	Apr. 22	BU
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	Mar. 25	AQ
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	Mar. 22	BU
Sangamo: Q4 Earnings Snapshot	Mar. 13	AQ
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	Mar. 13	BU
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs	Mar. 13	BU
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast	Mar. 12	BU
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease	Feb. 12	BU
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile	Feb. 05	BU
Sangamo Therapeutics : Corporate Presentation	Nov. 01	PU
Sangamo: Q3 Earnings Snapshot	Nov. 01	AQ
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results	Nov. 01	BU
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast	23-10-25	BU
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene and Cell Therapy	23-10-25	AQ
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)	23-10-24	BU
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer	23-10-18	AQ
Sangamo Therapeutics to Present at the Jefferies Cell and Genetic Medicine Summit	23-09-21	AQ
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit	23-09-20	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Press Releases

Filters